ClinicalTrials.gg
RecruitingNCT05598112STEP-agingUpdated Dec 31, 2025

Effect of Gut Microbiome Intervention on Aging Via Oral FMT

An Early Phase 1 interventional study of FMT capsules and Placebo capsules in Aging and Frailty, sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. Recruiting at 6 sites in China. Open to participants aged 70 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
70 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Frailty with a site in China — 26 open to participants now, 28 under way, none of them phase 3. Frailty · China.

Planned enrollment
10th of 32
210 · median 146
Started
2023
with 8 others
Phase 1
2 of 65
1 open now
Primary completion
2026-12
later than 13 of 27 live
Registered
22nd of 65
by date

Among the 65 studies in Frailty with a site in China, this one is the 10th largest by planned enrollment of the 32 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 1, reaches primary completion later than 13 of the 27 other live ones, and was the 22nd registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

26 of the 65 studies in Frailty with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 70 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Frailty with a site in China, or all of them as a file.
02

Study summary

A severe public health issue facing global population is aging. Increasing preclinical and clinical data indicate the contribution of gut microbiome on aging and aging-related diseases such as cardiovascular disease, Alzheimer Disease, and diabetes. Interventions on microbiota are developed including prebiotics, probiotics, and fecal microbial transplantation (FMT). FMT via oral capsules also advances in recent with limited safety concerns compared with invasive routes. A hypothesis is thus raised that gut microbiome intervention via oral FMT can be a potential safe approach to encourage healthy aging, with multiple aspects evaluated for clinical phenotype of frailty, anthropometric measurement, cognitive function, cardiovascular aging, physical function, living activity, hippocampal volume, telomere length, cognitive biomarkers, inflammatory biomarkers, altered microbial composition and metabolites.

Read the detailed description

Objective: To explore the effect, safety and underlying mechanisms of gut microbiome intervention via FMT on aging. Study Design: A multi-center, randomized, blinded, placebo-controlled pilot study. Data quality control and statistical analysis: The investigators have invited professional statistic analysts to assist analyzing data and a third party to supervise data quality. Ethics: The Ethics Committee of Fuwai Hospital approved this study. Informed consents before patient enrollment are required.

03

Conditions studied

  • Aging
  • Frailty

Browse trials for

Keywords

  • Aging
  • Frailty
  • Microbiome
  • Treatment
  • Fecal Microbiota Transplantation
04

Who can participate

Ages eligible
70 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 70-85 years.
  2. Patients with after thorough explanation.

Exclusion criteria

Exclusion Criteria:

  1. Participants of other clinical trials;
  2. Antibiotics or probiotics usage within last 4 weeks;
  3. Severe hepatic or renal diseases (( >3 times the value, or end stage renal disease on dialysis or \<30 mL/min/1.73 m2, or serum creatinine >2.5 mg/dl [>221 μmol/L]);
  4. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and [TIA]);
  5. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;
  6. class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months;
  7. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;
  8. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease;
  9. History of dementia, Parkinson's disease, intracranial infection, intracranial tumor, schizophrenia, anxiety, depression;
  10. History of neurosurgical operation;
  11. History of gastrointestinal tumor, gastrointestinal surgery, inflammatory bowel disease; Hospitalization for peptic ulcer disease exacerbation within last 6 months or anticipated hospitalization for peptic ulcer disease the next 6 months;
  12. Hypertension with uncontrolled blood pressure ≥180/110mmHg;
  13. Diabetes Mellitus with uncontrolled fasting glucose level ≥200mg/dl (11.1mmol/L), or >8%;
  14. Addicted to alcohol; Use of medication influencing cognitive function(i.e., antihistamine, antipsychotic);
  15. General anesthesia within last 3 months;
  16. Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome, \<1 year;
  17. Impaired verbal communication who are incapable of providing their own , or incapable of self-care;
  18. Special diet influencing microbiota (i.e. vegetarian);
  19. Other conditions inappropriate for recruitment according to the investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    FMT capsules

    FMT capsules containing extensively screened donor stool. FMT capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 28, week 32, week 36, week 48, week 52, week 56, week 60, week 72, week 76, week 80, week 84.

    Biological: FMT capsules

  • Placebo comparator
    Placebo capsules

    Placebo capsules that do not contain donor stool or any active drug. Placebo capsules will be orally taken on week 0, week 4, week 8, week 12, week 24, week 28, week 32, week 36, week 48, week 52, week 56, week 60, week 72, week 76, week 80, week 84.

    Other: Placebo capsules

Interventions

  • BiologicalFecal microbiotaStudies of Fecal microbiotaFecal microbiota pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    FMT capsules containing extensively screened donor stool.

  • OtherPlacebo capsules

    Placebo capsules that do not contain donor stool or any active drug.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with reduced frailty score at week 96 follow-up

    Frailty score via CHS criteria of five frailty components, compared with baseline

    Time frame: week 96

Secondary outcomes

  1. Proportion of participants with reduced frailty score at week 12 follow-up

    Frailty score via CHS criteria of five frailty components, compared with baseline

    Time frame: week 12

  2. Proportion of participants with reduced frailty score at week 24 follow-up

    Frailty score via CHS criteria of five frailty components, compared with baseline

    Time frame: week 24

  3. Proportion of participants with reduced frailty score at week 48 follow-up

    Frailty score via CHS criteria of five frailty components, compared with baseline

    Time frame: week 48

  4. Proportion of participants with reduced frailty score at week 72 follow-up

    Frailty score via CHS criteria of five frailty components, compared with baseline

    Time frame: week 72

  5. Change from baseline in Frailty score

    Frailty score via CHS criteria of five frailty components, ranging from 0 to 5, with higher score indicating worse outcome

    Time frame: week 12, week 24, week 48, week 72, week 96, compared with baseline

  6. Change from baseline in telomere length

    Change from baseline in telomere length

    Time frame: week 48, week 96

  7. Change from baseline in Cognitive assessment via Mini Mental State Examination(MMSE)

    MMSE (Mini Mental State Examination) ranging from 0 to 30, with lower score indicating worse outcome

    Time frame: week 24, week 48, week 72, week 96, compared with baseline

  8. Change from baseline in Cognitive assessment via Montreal Cognitive Assessment(MoCA)

    MoCA (Montreal Cognitive Assessment) ranging from 0 to 30, with lower score indicating worse outcome

    Time frame: week 24, week 48, week 72, week 96, compared with baseline

  9. Change from baseline in Hippocampal volumes

    Hippocampal volumes evaluated by Magnet Resonance Imaging

    Time frame: week 48, week 96

  10. Change from baseline in cognitive biomarkers

    plasma levels of cognitive biomarkers for BDNF、tau、Aβ-40、Aβ42

    Time frame: week 12, week 24, week 48, week 72, week 96

  11. Change from baseline in inflammatory biomarkers

    plasma levels of inflammatory biomarkers for hs-C-reactive protein (hs-CRP)、 interleukin 6(IL-6)、interleukin 1 β(IL-1 β) 、interleukin10 (IL-10)、tumor necrosis factor α(TNF-α)

    Time frame: week 12, week 24, week 48, week 72, week 96

  12. Change from baseline in Intestinal Microbiota Composition Pre- and Post-intervention via Metagenomic Analysis

    Change in Intestinal Microbiota Composition Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by: 1. Randomisation 2. Change in Office SBP

    Time frame: week 12, week 24, week 48, week 72, week 96

  13. Change from baseline in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention via Metagenomic Analysis

    Change in Intestinal Microbiota Function assessed by KEGG Orthology (KO) Pre- and Post-intervention (FMT or Placebo) via Metagenomic Analysis, stratified by: 1. Randomisation 2. Change in Office SBP

    Time frame: week 12, week 24, week 48, week 72, week 96

  14. Change from baseline in Plasma Metabolite Composition Pre- and Post-intervention via Metabolomic Analysis

    Change in Plasma Metabolite Composition Pre-and Post-intervention (FMT or Placebo) via Metabolomic Analysis

    Time frame: week 12, week 24, week 48, week 72, week 96

  15. Change from baseline in Ankle-Brachial Blood Pressure Index(ABI)

    Change for ABI as an objective measurement of arterial insufficiency based on the ratio of ankle systolic pressure to brachial systolic pressure.

    Time frame: week 48, week 96

  16. Change from baseline in Pulse wave velocity(PWV)

    Change for Pulse wave velocity(PWV)

    Time frame: week 48, week 96

  17. Number of Participants with Adverse Events (AEs) as a Measure of Safety

    Number of Participants with Adverse Events (AEs) as a Measure of Safety

    Time frame: week 12, week 24, week 48, week 72, week 96

  18. Change from baseline in Body Mass Index (BMI)

    Change for Body Mass Index

    Time frame: week 4, week 8, week 12, week 24, week 48, week 72, week 96

  19. Change from baseline in office SBP

    change for office systolic blood pressure(SBP)

    Time frame: week 4, week 8, week 12, week 24, week 48, week 72, week 96

  20. Change from baseline in office DBP

    change for office diastolic blood pressure(DBP)

    Time frame: week 4, week 8, week 12, week 24, week 48, week 72, week 96

  21. Change from baseline in Blood Lipid Level

    Change for Blood Lipid Level (Total Cholesterol, Total Triglyceride, Low Density Lipoprotein Cholesterol, High Density Lipoprotein Cholesterol)

    Time frame: week 12, week 24, week 48, week 96

  22. Change from baseline in blood fasting glucose level

    Change for blood fasting glucose level

    Time frame: week 12, week 24, week 48, week 96

  23. Change from baseline in blood HbA1c level

    Change for blood glycosylated hemoglobin, type A1C (HbA1c) level

    Time frame: week 12, week 24, week 48, week 96

  24. Change from baseline in physical function assessment via 6MWT

    6-minute walking test(6MWT)

    Time frame: week 12, week 24, week 48, week 72, week 96

  25. Change from baseline in daily function assessment via Activity of Daily Living (ADL)

    Activity of Daily Living (ADL) ranging from 0 to 100, with lower score indicating worse outcome

    Time frame: week 12, week 24, week 48, week 72, week 96

07

Study locations

6 of 6 sites recruiting
08

References and documents

Publications

  • Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146. PubMed 11253156 ↗
  • Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri M, Giampieri E, Jennings A, Candela M, Turroni S, Zoetendal EG, Hermes GDA, Elodie C, Meunier N, Brugere CM, Pujos-Guillot E, Berendsen AM, De Groot LCPGM, Feskins EJM, Kaluza J, Pietruszka B, Bielak MJ, Comte B, Maijo-Ferre M, Nicoletti C, De Vos WM, Fairweather-Tait S, Cassidy A, Brigidi P, Franceschi C, O'Toole PW. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut. 2020 Jul;69(7):1218-1228. doi: 10.1136/gutjnl-2019-319654. Epub 2020 Feb 17. PubMed 32066625 ↗
  • Ng TP, Feng L, Nyunt MS, Feng L, Niti M, Tan BY, Chan G, Khoo SA, Chan SM, Yap P, Yap KB. Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial. Am J Med. 2015 Nov;128(11):1225-1236.e1. doi: 10.1016/j.amjmed.2015.06.017. Epub 2015 Jul 6. PubMed 26159634 ↗
  • Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018 Nov;67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. Epub 2018 Aug 28. PubMed 30154172 ↗
  • Kundu P, Lee HU, Garcia-Perez I, Tay EXY, Kim H, Faylon LE, Martin KA, Purbojati R, Drautz-Moses DI, Ghosh S, Nicholson JK, Schuster S, Holmes E, Pettersson S. Neurogenesis and prolongevity signaling in young germ-free mice transplanted with the gut microbiota of old mice. Sci Transl Med. 2019 Nov 13;11(518):eaau4760. doi: 10.1126/scitranslmed.aau4760. PubMed 31723038 ↗

Individual participant data

Plan to share: Yes — The collected data, study protocol, and SAP are planned to be shared after the study ends 3 years later (anticipated)

Supporting information: Study protocol, Statistical analysis plan

Time frame: after the study ends 3 years later (anticipated)

Access criteria: Access to these deidentified data will be required for written permission from the responsible investigation center and only for qualified researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2022
First posted
Oct 28, 2022
StartActual
Apr 24, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05598112
Responsible party
Jun Cai (Director, Beijing Anzhen Hospital) — Principal investigator
First posted
Oct 28, 2022
Start date
Apr 24, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Luyun Fan, MD,PhD
Contact
katevan@163.com
01081992131
Jun Cai, MD,PhD
Contact
caijun7879@126.com
Jun Cai, MD,PhD
principal investigator · Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Chinese Institutes for Medical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fecal microbiota

Start the discussion